IONS - Ionis gains as anti-lipid therapy undergoes FDA priority review
2024-06-25 15:39:29 ET
More on Ionis Pharmaceuticals
- Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
- Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
- ALS therapy market seen increasing to nearly $1.3B by 2029
- Ionis hereditary angioedema therapy succeeds in late-stage trials
- Seeking Alpha’s Quant Rating on Ionis Pharmaceuticals